-
Product Insights
New![]()
Net Present Value Model: TScan Therapeutics Inc’s TSC-100/TSC-101
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.Drug Operating Profit Model
-
Product Insights
New![]()
Net Present Value Model: TScan Therapeutics Inc’s TSC-200-A0201
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TSC-101 in Myelodysplastic Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TSC-101 in Myelodysplastic Syndrome Drug Details:TSC-101 is under development for the treatment of blood cancers like...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TSC-100 in Myelodysplastic Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TSC-100 in Myelodysplastic Syndrome Drug Details:TSC-100 is under development for the treatment of blood cancers like...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TSC-204-C0702 in Cervical Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TSC-204-C0702 in Cervical Cancer Drug Details: TSC-204-C0702 is under development for the treatment of head...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TSC-204-C0702 in Metastatic Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TSC-204-C0702 in Metastatic Melanoma Drug Details: TSC-204-C0702 is under development for the treatment of head...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TSC-204-C0702 in Anal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TSC-204-C0702 in Anal Cancer Drug Details: TSC-204-C0702 is under development for the treatment of head...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TSC-200-A0201 in Cervical Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TSC-200-A0201 in Cervical Cancer Drug Details: TSC-200 is under development for the treatment of HPV-positive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TSC-200-A0201 in Metastatic Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TSC-200-A0201 in Metastatic Melanoma Drug Details: TSC-200 is under development for the treatment of HPV-positive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TSC-200-A0201 in Anal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TSC-200-A0201 in Anal Cancer Drug Details: TSC-200 is under development for the treatment of HPV-positive...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.